Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Fiche publication
Date publication
mars 2010
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HOULGATTE Rémy, Dr ROLLAND Delphine
Tous les auteurs :
Rolland D, Ribrag V, Haioun C, Ghesquieres H, Jardin F, Bouabdallah R, Franchi P, Briere J, De Kerviler E, Chassagne-Clement C, Raponi M, Houlgatte R, Jais JP, Thieblemont C
Lien Pubmed
Résumé
Farnesyltransferase (Ftase) was identified by gene-expression profiling and by preclinical evaluation in in vitro and in vivo mantle cell lymphoma (MCL) models as a rational therapeutic target in MCL, one of the most refractory B-cell lymphomas. We conducted a multicenter phase II study of a potent Ftase inhibitor, tipifarnib, in patients with relapsed or refractory MCL.
Mots clés
A Kinase Anchor Proteins, genetics, Administration, Oral, Aged, Antineoplastic Agents, administration & dosage, DNA-Binding Proteins, genetics, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, drug effects, Guanine Nucleotide Exchange Factors, genetics, Humans, Lymphoma, Mantle-Cell, drug therapy, Male, Minor Histocompatibility Antigens, Neoplasm Recurrence, Local, Nuclear Proteins, genetics, Predictive Value of Tests, Prognosis, Prospective Studies, Proto-Oncogene Proteins, genetics, Quinolones, administration & dosage, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, Treatment Outcome
Référence
Cancer Chemother. Pharmacol.. 2010 Mar;65(4):781-90